PUBLISHER: KBV Research | PRODUCT CODE: 1245580
PUBLISHER: KBV Research | PRODUCT CODE: 1245580
The Asia Pacific Sciatica Treatment Market would witness market growth of 4.3% CAGR during the forecast period (2022-2028).
The growing popularity of sciatica treatments in the automobile sector, rising consumer desire for more fuel-efficient engines, increasing use of electric cars, and other factors are all contributing to the potential development of the sciatica treatment market during the anticipated period. Researchers involved in creating a new intervention are a driving force behind the acceleration of market expansion. The intense desire for disease-specific innovative treatments further boosts the total market demand for this category. The development of medications used to treat sciatica-related problems is another driving force.
Also, the population has access to various indoor professions because of expanding industry. Because of the increasing burden, the working population spends much time sitting down. Long periods of sitting may cause sciatica to develop or become worse. As a result, the increasing number of people in the workforce may encourage the spread of sciatica treatments. Moreover, sacral and lumbar spinal tumors may cause leg paralysis and sciatic back discomfort. Thus, throughout the scheduled time, the increased incidence of cancer among the population may provide new chances for the sciatica treatment market.
One of the world's fastest-growing aging populations is in China. Due to rising life expectancy and falling birth rates, 28% of China's population is expected to be over 60 by 2040. The creation of age-friendly towns and communities where older people may flourish and continue to make significant contributions to society is essential due to the increasingly aging population. In addition, there is an increase in demand for sciatica therapy in the APAC area due to the region's aging population and growing osteoarthritis prevalence.
The China market dominated the Asia Pacific Sciatica Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $62,929.5 Thousands by 2028. The Japan market is estimated to grow a CAGR of 3.6% during (2022 - 2028). Additionally, The India market would display a CAGR of 4.9% during (2022 - 2028).
Based on Type, the market is segmented into Chronic, Acute and Others. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies and Online Providers. Based on Drug Class, the market is segmented into Non-Steroidal anti-inflammatory, Steroids, Antidepressants and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
Market Segments covered in the Report:
By Type
By Distribution Channel
By Drug Class
By Country
Companies Profiled
Unique Offerings from KBV Research
List of Figures